https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Antiviral immunity is impaired in COPD patients with frequent exacerbations https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36808 Thu 04 Nov 2021 10:39:56 AEDT ]]> Beclomethasone has lesser suppressive effects on inflammation and antibacterial immunity than fluticasone or budesonide in experimental infection models https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38861 Streptococcus pneumoniae, mechanistically through inhibition of the antimicrobial peptide (AMP) cathelicidin. Using experiments in human cells and mouse infection models, we performed a head-to-head comparison of the effects of the major ICS agents used in COPD on innate immunity.]]> Mon 29 Jan 2024 17:53:07 AEDT ]]> Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42308 Camp-/-) and exogenous cathelicidin prevented ICS-mediated expansion of streptococci within the microbiota and improved bacterial clearance. Suppression of pulmonary immunity by ICS was mediated by augmentation of the protease cathepsin D. Collectively, these data suggest a central role for cathepsin D/cathelicidin in the suppression of antibacterial host defense by ICS in COPD. Therapeutic restoration of cathelicidin to boost antibacterial immunity and beneficially modulate the lung microbiota might be an effective strategy in COPD.]]> Mon 22 Aug 2022 10:35:15 AEST ]]>